Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALDX
Nasdaq
8731
https://www.aldeyra.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aldeyra Therapeutics Inc
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Apr 25th, 2024 11:00 am
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
- Apr 22nd, 2024 1:40 pm
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Apr 18th, 2024 11:00 am
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
- Apr 6th, 2024 10:37 am
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
- Apr 5th, 2024 1:40 pm
Health Care Roundup: Market Talk
- Apr 4th, 2024 4:36 pm
Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval
- Apr 3rd, 2024 6:58 pm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner
- Apr 3rd, 2024 11:17 am
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
- Mar 28th, 2024 11:00 am
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
- Mar 13th, 2024 6:33 am
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
- Mar 6th, 2024 2:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
- Mar 4th, 2024 2:40 pm
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
- Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry
- Feb 29th, 2024 1:53 pm
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company
- Feb 22nd, 2024 12:35 pm
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 12:00 pm
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
- Jan 4th, 2024 12:00 pm
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
- Dec 19th, 2023 12:00 pm
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
- Dec 18th, 2023 9:01 pm
13 Hot Penny Stocks To Buy According to Hedge Funds
- Dec 6th, 2023 4:55 pm
Scroll